Name: The Drug Development Paradigm in Oncology. Proceedings of a Workshop
SKU: 65388242
Price: 47.38 EUR
Availability: InStock
Author: Board on Health Care Services;Sharyl J. Nass;Margie Patlak;Erin Balogh;Amanda Wagner Gee;National Cancer Policy Forum;National Academies of Sciences Engineering and Medicine;Health and Medicine Division
ISBN: 9780309457941

portada The Drug Development Paradigm in Oncology. Proceedings of a Workshop

The Drug Development Paradigm in Oncology. Proceedings of a Workshop

Formato

Libro Físico

Editorial

National Academies Press

Autor

Board on Health Care Services;Sharyl J. Nass;Margie Patlak;Erin Balogh;Amanda Wagner Gee;National Cancer Policy Forum;National Academies of Sciences Engineering and Medicine;Health and Medicine Division

Año

2018

N° páginas

144

Encuadernación

Tapa Blanda

Dimensiones

22.9x15.2x2.5 cm

ISBN13

9780309457941

The Drug Development Paradigm in Oncology. Proceedings of a Workshop

Board On Health Care Services;Sharyl J. Nass;Margie Patlak;Erin Balogh;Amanda Wagner Gee;National Cancer Policy Forum;National Academies Of Sciences Engineering And Medicine;Health And Medicine Division (Autor) · National Academies Press · Tapa Blanda

Libro Nuevo Origen: España

Envío: 6 a 7 días háb.

49,87 €47,38 €

-5%

Libro Nuevo

Quedan 50 unidades

47,38 €

Llega entre el 10 Nov y el 13 Nov a Provincia de Madrid. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "The Drug Development Paradigm in Oncology. Proceedings of a Workshop"

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of efforts—by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)—to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop. Table of ContentsFront MatterProceedings of a WorkshopAppendix A: Statement of TaskAppendix B: Workshop Agenda